There are currently 1303 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Children's Health Care of Atlanta and Emory University Hospital/Winship Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Recruiting
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Neuroblastoma Biology Study
Recruiting
Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma... Read More
Gender:
ALL
Ages:
Between 31 days and 99 years
Trial Updated:
09/01/2024
Locations: AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia
Conditions: Neuroblastoma
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Recruiting
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical start... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Emory University - Winship Cancer Institute, Atlanta, Georgia
Conditions: Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
Recruiting
The HEMERA-1 Extension (Part III) is a prospective, open-label, multicenter study to evaluate safety of two doses of PP-007 in Acute Ischemic Stroke (AIS) subjects receiving Intravenous Thrombolysis (IVT) or mechanical thrombectomy (MT) or IVT+MT as standard of care (SOC). Subjects will receive two doses of PP-007 infusion 24 ± 6 hours apart in addition to the site-specific SOC protocol. PP-007 is PEGylated bovine carboxyhemoglobin and will be administered via IV infusion. The effects on collate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Acute Ischemic Stroke
Gamma Sensory Flicker for Parkinson's Disease Patients With Freezing of Gait
Recruiting
This study aims to answer the question: to assess the safety, and tolerability of gamma light in Parkinson's disease (PD) patients with freezing of gait (FOG). Parkinson's disease (PD) patients often experience a complex gait disorder known as Freezing of Gait (FOG). FOG is characterized by brief arrests of stepping when initiating gait, turning, and walking straight and patients describe it as their feet being "glued" to the floor. FOG in Parkinson's disease (PD) is a considerable public healt... Read More
Gender:
ALL
Ages:
Between 50 years and 75 years
Trial Updated:
08/27/2024
Locations: Emory Movement Disorders Center, Atlanta, Georgia
Conditions: Gait Disorders, Neurologic, Parkinson Disease
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Recruiting
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-thre... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/27/2024
Locations: Piedmont Healthcare, Atlanta, Georgia
Conditions: Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
Recruiting
This research study will investigate whether dasiglucagon as a rescue therapy for participants under 6 years of age works and is safe to use. In addition, the study will investigate how dasiglucagon works in the body (pharmacokinetics and pharmacodynamics). Participants will receive 1 single dose as an injection under the skin (subcutaneous, s.c.) into the buttocks. Participants will have 3 visits with the study team. For each participant, the study will last up to 84 days.
Gender:
ALL
Ages:
5 years and below
Trial Updated:
08/27/2024
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Hypoglycemia, Type 1 Diabetes
Sleep Enhancement for Older Adults Living With Memory Loss And Their Care Partners
Recruiting
The purpose of this study is to determine if a 6-week videoconference intervention to teach skills to improve sleep is practical, acceptable, and helpful to persons living with memory loss, cognitive impairment, and/or dementia and care partners, individually or together.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Emory Healthcare System, Atlanta, Georgia
Conditions: Sleep Disturbance, Dementia
A Beta-only IL-2 ImmunoTherapY Study
Recruiting
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Emory - Winship Cancer Institute, Atlanta, Georgia
Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Cutaneous Melanoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, Colorectal Cancer (MSI-H), MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer
Effects of Triiodothyronine (T3) in Ischemic Heart Failure
Recruiting
This study aims to determine whether giving triiodothyronine (T3), a thyroid hormone, is safe and helps improve symptoms and signs of heart failure. The study is divided into 2 phases. In the first phase, participants have a 50-50 chance of receiving the study drug. Participants who are enrolled to receive the study drug will be admitted to the General Clinical Research Center (GCRC) for 5 days for oral thyroid hormone treatment and monitoring. They will have 4 additional follow-up visits over... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/26/2024
Locations: Emory University Hospital (EUH), Atlanta, Georgia +1 locations
Conditions: Heart Failure
Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation
Recruiting
This clinical trial tests the feasibility, implementation and acceptability of chaplain delivered compassion meditation in order to improve spiritual care for patients receiving stem cell transplantation. Hospital chaplains play a vital role in delivering emotional and spiritual care to a broad range of both religious and non-religious patients for a wide variety of stressors, and extensive research indicates that spiritual consults impact patient outcomes and satisfaction. Compassion meditation... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Lymphoma, Multiple Myeloma